Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Preclinical News

Group identifies S6K1 as potential target for CNS injury

Julian Zhu
July 27, 2017 8:11 PM UTC

In a paper published in the Journal of Neuroscience, researchers at the University of Miami Miller School of Medicine and colleagues showed that targeting ribosomal protein S6 kinase 70kDa polypeptide 1 (RPS6KB1; S6K1) could help treat CNS injuries by promoting neuronal regeneration.

The group showed that S6K1 inhibition with PF-4708671 in primary hippocampal neurons significantly increased total length of neurite outgrowths compared with vehicle controls. The effect was also achieved through siRNA-mediated knockdown of S6K1...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Indiana University

Merck KGaA

Pfizer Inc.

University of Miami Miller School of Medicine